Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Feb 17;78(2):353–363. doi: 10.1111/bcp.12349

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Prothrombin time (PT) expressed in seconds (A) and international normalized ratio (INR; B) after the administration of warfarin (INR 2.0–3.0) followed by rivaroxaban 20 mg once daily (od; treatment A), warfarin (INR 2.0–3.0) followed by placebo od (treatment B) and rivaroxaban alone 20 mg od (treatment C); relative prolongation is expressed as median ratio to baseline (n = 26–28). , warfarin/rivaroxaban; , warfarin/placebo; , rivaroxaban alone

Inline graphic — Prothrombin time (PT) expressed in seconds (A) and international normalized ratio (INR; B) after the administration of warfarin (INR 2.0–3.0) followed by rivaroxaban 20 mg once daily (od; treatment A), warfarin (INR 2.0–3.0) followed by placebo od (treatment B) and rivaroxaban alone 20 mg od (treatment C); relative prolongation is expressed as median ratio to baseline (n = 26–28). , warfarin/rivaroxaban; , warfarin/placebo; , rivaroxaban alone